Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127138901 | 12713890 | 1 | I | 20160829 | 20160905 | 20160905 | EXP | JP-AMGEN-JPNSP2016116459 | AMGEN | MURAYAMA T. A RANDOMIZED, DOUBLE-BLIND TRIAL OF PEGFILGRASTIM VERSUS FILGRASTIM FOR THE MANAGEMENT OF NEUTROPENIA DURING CHASE(R) CHEMOTHERAPY FOR MALIGNANT LYMPHOMA. BRITISH JOURNAL OF HAEMATOLOGY. 2016;174 (4):563-570 | 0.00 | Y | 0.00000 | 20160904 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127138901 | 12713890 | 1 | PS | pegfilgrastim | PEGFILGRASTIM | 1 | Subcutaneous | 3.6 MG, UNK | U | 125031 | 3.6 | MG | UNKNOWN FORMULATION | ||||||
| 127138901 | 12713890 | 2 | SS | filgrastim | FILGRASTIM | 1 | Unknown | 50 MUG/M2, UNK | U | 0 | 50 | UG/M**2 | UNKNOWN FORMULATION | ||||||
| 127138901 | 12713890 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Intravenous (not otherwise specified) | 40 MG, UNK (ON DAY 1-3) | 0 | 40 | MG | ||||||||
| 127138901 | 12713890 | 4 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | 100 MG/M2, UNK | 0 | 100 | MG/M**2 | ||||||||
| 127138901 | 12713890 | 5 | SS | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 2000 MG/M2, UNK (ON DAY 2-3) | 0 | 2000 | MG/M**2 | ||||||||
| 127138901 | 12713890 | 6 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 1200 MG/M2, UNK | 0 | 1200 | MG/M**2 | ||||||||
| 127138901 | 12713890 | 7 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127138901 | 12713890 | 1 | Neutropenia |
| 127138901 | 12713890 | 2 | Neutropenia |
| 127138901 | 12713890 | 3 | Lymphoma |
| 127138901 | 12713890 | 4 | Lymphoma |
| 127138901 | 12713890 | 5 | Lymphoma |
| 127138901 | 12713890 | 6 | Lymphoma |
| 127138901 | 12713890 | 7 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127138901 | 12713890 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127138901 | 12713890 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |